BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, de Witte T, Farge-Bancel D, Gaspar B, Marsh J, Mohty M, Peters C, Tichelli A, Velardi A, de Elvira CR, Falkenburg F, Sureda A, Madrigal A; European Group for Blood and Marrow Transplantation (EBMT). The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012;47:906-23. [PMID: 22543746 DOI: 10.1038/bmt.2012.66] [Cited by in Crossref: 141] [Cited by in F6Publishing: 133] [Article Influence: 14.1] [Reference Citation Analysis]
Number Citing Articles
1 Sheshadri A, Sacks NC, Healey BE, Raza S, Boerner G, Huang HJ. Lung Function Monitoring After Lung Transplantation and Allogeneic Hematopoietic Stem Cell Transplantation. Clin Ther 2022:S0149-2918(22)00115-1. [PMID: 35513911 DOI: 10.1016/j.clinthera.2022.03.011] [Reference Citation Analysis]
2 El-Kadiry AE, Rafei M, Shammaa R. Cell Therapy: Types, Regulation, and Clinical Benefits. Front Med (Lausanne) 2021;8:756029. [PMID: 34881261 DOI: 10.3389/fmed.2021.756029] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
3 Kunadt D, Stölzel F. Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Cancer Manag Res 2021;13:7411-27. [PMID: 34594134 DOI: 10.2147/CMAR.S261721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Eftychidis I, Sakellari I, Anagnostopoulos A, Gavriilaki E. Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis. Expert Rev Hematol 2021. [PMID: 34388057 DOI: 10.1080/17474086.2021.1968823] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Robak O, Kastner MT, Stecher C, Schneider M, Andreas M, Greinix H, Kallay E, Honsig C, Steininger C. Cytomegalovirus Infection Downregulates Vitamin D Receptor in Patients Undergoing Hematopoietic Stem Cell Transplantation. Transplantation 2021;105:1595-602. [PMID: 32890131 DOI: 10.1097/TP.0000000000003448] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 García-Bernal D, Palomo M, Martínez CM, Millán-Rivero JE, García-Guillén AI, Blanquer M, Díaz-Ricart M, Sackstein R, Carreras E, Moraleda JM. Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease. J Cell Mol Med 2020;24:8031-44. [PMID: 32519822 DOI: 10.1111/jcmm.15434] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
7 Kim M, Shin M. Effect of Educational Program on Knowledge, Attitude, and Willingness of Nursing Students for Hematopoietic Stem-Cell Donation. Int J Environ Res Public Health 2019;16:E3696. [PMID: 31581423 DOI: 10.3390/ijerph16193696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Radujkovic A, Dietrich S, Blok HJ, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, Passweg J, Byrne JL, Jindra P, Veelken JH, Socié G, Maertens J, Schaap N, Stadler M, Itälä-Remes M, Tholouli E, Arat M, Rocha V, Ljungman P, Yakoub-Agha I, Kröger N, Chalandon Y. Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant 2019;25:2008-16. [PMID: 31271884 DOI: 10.1016/j.bbmt.2019.06.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Hermann A, Winkler A, Paschen C, Kuzmina Z, Hladik A, Icme S, Robak O. Lipocalin-2 levels in acute and chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Exp Hematol 2019;74:25-32.e1. [PMID: 31078634 DOI: 10.1016/j.exphem.2019.05.001] [Reference Citation Analysis]
10 Bacigalupo A, Sica S, Laurenti L, Sora' F, Giammarco S, Metafuni E, Innocenti I, Autore F, Teofili L, Bianchi M, Chiusolo P. Unrelated cord blood transplantation and post-transplant cyclophosphamide. Haematologica 2019;104:e77-8. [PMID: 30573505 DOI: 10.3324/haematol.2018.202598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
11 Frascino AV, Fava M, Cominato L, Odone-Filho V. Review of a three-year study on the dental care of onco-hematological pediatric patients. Clinics (Sao Paulo) 2018;73:e721. [PMID: 30517306 DOI: 10.6061/clinics/2017/e721] [Reference Citation Analysis]
12 Redjoul R, Robin C, Foulet F, Leclerc M, Beckerich F, Cabanne L, di Blasi R, Pautas C, Toma A, Botterel F, Maury S, Cordonnier C. Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always follow the guidelines? Bone Marrow Transplant 2019;54:1082-8. [PMID: 30413810 DOI: 10.1038/s41409-018-0391-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Poręba M, Gać P, Usnarska-Zubkiewicz L, Pilecki W, Kuliczkowski K, Mazur G, Gonerska M, Sobieszczańska M, Poręba R. Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies. Med Oncol 2018;35:162. [PMID: 30382530 DOI: 10.1007/s12032-018-1221-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Estcourt LJ, Stanworth S, Doree C, Trivella M, Hopewell S, Murphy MF, Tinmouth A. Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 2014:CD010984. [PMID: 25722652 DOI: 10.1002/14651858.CD010984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Estcourt LJ, Crighton GL, Wood EM, Stanworth S, Trivella M, Doree C, Tinmouth A, Murphy MF. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 2014:CD010981. [PMID: 25722649 DOI: 10.1002/14651858.CD010981] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Estcourt LJ, Stanworth S, Doree C, Trivella M, Hopewell S, Murphy MF, Tinmouth A. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 2014:CD010983. [PMID: 25722651 DOI: 10.1002/14651858.CD010983] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yüksel MK, İlhan O. JACIE: A 20 year-old voluntary body functioning worldwide. Transfus Apher Sci 2018;57:153-8. [PMID: 29801765 DOI: 10.1016/j.transci.2018.04.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Dessels C, Alessandrini M, Pepper MS. Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape. Stem Cells Transl Med. 2018;7:643-650. [PMID: 29777574 DOI: 10.1002/sctm.17-0244] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
19 Kisecik Sengul Z, Altay N. Effect of parental depression level on children's quality of life after haematopoietic stem cell transplantation. Eur J Oncol Nurs 2017;31:90-5. [PMID: 29173833 DOI: 10.1016/j.ejon.2017.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Nowak J, Nestorowicz K, Graczyk-Pol E, Mika-Witkowska R, Rogatko-Koros M, Jaskula E, Koscinska K, Madej S, Tomaszewska A, Nasilowska-Adamska B, Szczepinski A, Halaburda K, Dybko J, Kuliczkowski K, Czerw T, Giebel S, Holowiecki J, Baranska M, Pieczonka A, Wachowiak J, Czyz A, Gil L, Lojko-Dankowska A, Komarnicki M, Bieniaszewska M, Kucharska A, Hellmann A, Gronkowska A, Jedrzejczak WW, Markiewicz M, Koclega A, Kyrcz-Krzemien S, Mielcarek M, Kalwak K, Styczynski J, Wysocki M, Drabko K, Wojcik B, Kowalczyk J, Gozdzik J, Pawliczak D, Gwozdowicz S, Dziopa J, Szlendak U, Witkowska A, Zubala M, Gawron A, Warzocha K, Lange A. HLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donor. Hum Immunol 2018;79:403-12. [PMID: 29605688 DOI: 10.1016/j.humimm.2018.03.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
21 Suárez-González J, Martínez-Laperche C, Kwon M, Balsalobre P, Carbonell D, Chicano M, Rodríguez-Macías G, Serrano D, Gayoso J, Díez-Martín JL, Buño I. Donor Cell-Derived Hematologic Neoplasms after Hematopoietic Stem Cell Transplantation: A Systematic Review. Biol Blood Marrow Transplant 2018;24:1505-13. [PMID: 29410295 DOI: 10.1016/j.bbmt.2018.01.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
22 Monzel C, Becker AS, Saffrich R, Wuchter P, Eckstein V, Ho AD, Tanaka M. Dynamic cellular phynotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents. Sci Rep 2018;8:1841. [PMID: 29382856 DOI: 10.1038/s41598-018-19557-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kriegsmann K, Schmitt A, Kriegsmann M, Bruckner T, Anyanwu A, Witzens-Harig M, Müller-Tidow C, Klein S, Wuchter P. Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection.Biol Blood Marrow Transplant. 2018;24:1281-1288. [PMID: 29353110 DOI: 10.1016/j.bbmt.2018.01.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 van Haren IEPM, Staal JB, Potting CM, Atsma F, Hoogeboom TJ, Blijlevens NMA, Nijhuis-van der Sanden MWG. Physical exercise prior to hematopoietic stem cell transplantation: A feasibility study. Physiotherapy Theory and Practice 2018;34:747-56. [DOI: 10.1080/09593985.2018.1423655] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
25 Nivison-smith I, Milliken S, Dodds AJ, Gottlieb D, Kwan J, Ma DD, Shaw PJ, Tran S, Wilcox L, Szer J. Activity and Capacity Profile of Transplant Physicians and Centers in Australia and New Zealand. Biology of Blood and Marrow Transplantation 2018;24:169-74. [DOI: 10.1016/j.bbmt.2017.09.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
26 Gu G, Yang J, Sun L. Correlation of graft immune composition with outcomes after allogeneic stem cell transplantation: Moving towards a perfect transplant. Cellular Immunology 2018;323:1-8. [DOI: 10.1016/j.cellimm.2017.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
27 Lee CJ, Savani BN, Mohty M, Labopin M, Ruggeri A, Schmid C, Baron F, Esteve J, Gorin NC, Giebel S, Ciceri F, Nagler A. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 2017;102:1810-22. [PMID: 28883081 DOI: 10.3324/haematol.2017.176107] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
28 Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois C, Bay J, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich P, N’guyen S, Maillard N, Marchand T, Mohty M, Chevallier P. Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Annals of Oncology 2017;28:2191-8. [DOI: 10.1093/annonc/mdx274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
29 Jo T, Arai Y, Kondo T, Kitano T, Hishizawa M, Yamashita K, Takaori-Kondo A. Chronic Kidney Disease in Long-Term Survivors after Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis at a Single Institute. Biol Blood Marrow Transplant 2017;23:2159-65. [PMID: 28822830 DOI: 10.1016/j.bbmt.2017.08.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
30 Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, Gennery A, Kröger N, Kuball J, Lanza F, Montoto S, Nagler A, Snowden JA, Styczynski J, Mohty M. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant 2017;52:811-7. [PMID: 28287639 DOI: 10.1038/bmt.2017.34] [Cited by in Crossref: 210] [Cited by in F6Publishing: 217] [Article Influence: 42.0] [Reference Citation Analysis]
31 Morishita S, Kaida K, Yamauchi S, Wakasugi T, Ikegame K, Ogawa H, Domen K. Relationship of physical activity with physical function and health-related quality of life in patients having undergone allogeneic haematopoietic stem-cell transplantation. Eur J Cancer Care 2017;26:e12669. [DOI: 10.1111/ecc.12669] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
32 Deneys V, Fabry A, Van Hooydonk M, Sonet A, André M, Bourgeois M, Botson F. Efficiency of autologous stem cell collection: Comparison of three different cell separators. Transfus Apher Sci 2017;56:35-8. [PMID: 28111240 DOI: 10.1016/j.transci.2016.12.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
33 Atilla E, Ataca Atilla P, Demirer T. A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations. Balkan Med J 2017;34:1-9. [PMID: 28251017 DOI: 10.4274/balkanmedj.2017.0055] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
34 Estcourt LJ, Birchall J, Allard S, Bassey SJ, Hersey P, Kerr JP, Mumford AD, Stanworth SJ, Tinegate H; the British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol 2017;176:365-94. [DOI: 10.1111/bjh.14423] [Cited by in Crossref: 189] [Cited by in F6Publishing: 199] [Article Influence: 31.5] [Reference Citation Analysis]
35 Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M. Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2017;52:191-6. [PMID: 27819687 DOI: 10.1038/bmt.2016.258] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
36 Zuckerman T, Beyar-Katz O, Rowe JM. Should autotransplantation in acute myeloid leukemia in first complete remission be revisited? Curr Opin Hematol 2016;23:88-94. [PMID: 26825697 DOI: 10.1097/MOH.0000000000000212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
37 Desborough M, Estcourt LJ, Doree C, Trivella M, Hopewell S, Stanworth SJ, Murphy MF. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 2016;:CD010982. [PMID: 27548292 DOI: 10.1002/14651858.CD010982.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
38 Aloisio M, Licastro D, Caenazzo L, Torboli V, D'Eustacchio A, Severini GM, Athanasakis E. A technical application of quantitative next generation sequencing for chimerism evaluation. Mol Med Rep 2016;14:2967-74. [PMID: 27499173 DOI: 10.3892/mmr.2016.5593] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
39 Doehn JM, Winkler A, Kuzmina Z, Hladik A, Greinix H, Knapp S, Robak O. Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation. Exp Hematol 2016;44:917-23. [PMID: 27403536 DOI: 10.1016/j.exphem.2016.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
40 Robak O, Kuzmina Z, Winkler A, Kalhs P, Rabitsch W, Greinix H. Adiponectin and resistin in acute and chronic graft-vs-host disease patients undergoing allogeneic hematopoietic stem cell transplantation. Croat Med J 2016;57:255-65. [PMID: 27374827 DOI: 10.3325/cmj.2016.57.255] [Reference Citation Analysis]
41 Atsuta Y, Hirakawa A, Nakasone H, Kurosawa S, Oshima K, Sakai R, Ohashi K, Takahashi S, Mori T, Ozawa Y, Fukuda T, Kanamori H, Morishima Y, Kato K, Yabe H, Sakamaki H, Taniguchi S, Yamashita T; Late Effect and Quality of Life Working Group of the Japan Society for Hematopoietic Cell Transplantation. Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016;22:1702-9. [PMID: 27246369 DOI: 10.1016/j.bbmt.2016.05.019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
42 Le Bourgeois A, Peterlin P, Guillaume T, Delaunay J, Duquesne A, Le Gouill S, Moreau P, Mohty M, Campion L, Chevallier P. Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults. Biol Blood Marrow Transplant 2016;22:1473-9. [PMID: 27118570 DOI: 10.1016/j.bbmt.2016.04.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
43 Lisenko K, Pavel P, Bruckner T, Puthenparambil J, Hundemer M, Schmitt A, Witzens-Harig M, Ho AD, Wuchter P. Comparison between intermittent and continuous spectra optia leukapheresis systems for autologous peripheral blood stem cell collection. J Clin Apher 2017;32:27-34. [PMID: 27095367 DOI: 10.1002/jca.21463] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
44 Mallet V, van Bömmel F, Doerig C, Pischke S, Hermine O, Locasciulli A, Cordonnier C, Berg T, Moradpour D, Wedemeyer H, Ljungman P; ECIL-5. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 2016;16:606-17. [PMID: 27599653 DOI: 10.1016/S1473-3099(16)00118-3] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 14.5] [Reference Citation Analysis]
45 He F, Warlick E, Miller JS, MacMillan M, Verneris MR, Cao Q, Weisdorf D. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD. Bone Marrow Transplant 2016;51:1107-12. [PMID: 27064686 DOI: 10.1038/bmt.2016.63] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
46 Tan AM, Ha C, Li CF, Chan GC, Lee V, Tan PL, Hongeng S, Sanpakit K, Lee AC, Lin HP, el Rosario MLU, Chen J. Viva-Asia Blood and Marrow Transplantation Groups – A Survey of Consortium Activity over a 12-year Period (2000 to 2011). Ann Acad Med Singap 2016;45:106-9. [DOI: 10.47102/annals-acadmedsg.v45n3p106] [Reference Citation Analysis]
47 Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant 2016;51:786-92. [PMID: 26901709 DOI: 10.1038/bmt.2016.20] [Cited by in Crossref: 228] [Cited by in F6Publishing: 233] [Article Influence: 38.0] [Reference Citation Analysis]
48 Granata A, Drezet A, Faucher C, Lemarie C, Calmels B, Chabannon C. New developments in the use of apheresis to collect haematopoietic cells for cell transplantation and cell therapies. VOXS 2016;11:100-4. [DOI: 10.1111/voxs.12208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Ning B, Cheuk DK, Chiang AK, Lee PP, Ha SY, Chan GC. Autologous cord blood transplantation for metastatic neuroblastoma. Pediatr Transplant 2016;20:290-6. [PMID: 26694195 DOI: 10.1111/petr.12647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
50 Fedele R, Martino M, Recchia AG, Irrera G, Gentile M, Morabito F. Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. J Immunol Res 2015;2015:968212. [PMID: 26788526 DOI: 10.1155/2015/968212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
51 Bremm M, Cappel C, Erben S, Jarisch A, Schumm M, Arendt A, Bonig H, Klingebiel T, Koehl U, Bader P, Huenecke S. Generation and flow cytometric quality control of clinical-scale TCRαβ/CD19-depleted grafts: QUALITY CONTROL OF DEPLETED GRAFTS. Cytometry 2017;92:126-35. [DOI: 10.1002/cyto.b.21328] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
52 Chang X, Zang X, Xia CQ. New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. Bone Marrow Transplant 2016;51:324-32. [PMID: 26595077 DOI: 10.1038/bmt.2015.288] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
53 Estcourt LJ, Stanworth SJ, Doree C, Hopewell S, Trivella M, Murphy MF. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 2015;:CD010983. [PMID: 26576687 DOI: 10.1002/14651858.CD010983.pub2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
54 Platon L, Amigues L, Ceballos P, Fegueux N, Daubin D, Besnard N, Larcher R, Landreau L, Agostini C, Machado S, Jonquet O, Klouche K. A reappraisal of ICU and long-term outcome of allogeneic hematopoietic stem cell transplantation patients and reassessment of prognosis factors: results of a 5-year cohort study (2009–2013). Bone Marrow Transplant 2016;51:256-61. [DOI: 10.1038/bmt.2015.269] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
55 Lisenko K, Stadtherr P, Bruckner T, Pavel P, Heilig CE, Schmitt A, Puthenparambil J, Brandt J, Ho AD, Dreger P, Witzens-Harig M, Wuchter P. Bone Marrow Harvesting of Allogeneic Donors in an Outpatient Setting: A Single-Center Experience. Biol Blood Marrow Transplant 2016;22:470-4. [PMID: 26551634 DOI: 10.1016/j.bbmt.2015.10.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
56 Schuler M, Hornemann B, Pawandenat C, Kramer M, Hentschel L, Beck H, Kasten P, Singer S, Schaich M, Ehninger G, Platzbecker U, Schetelig J, Bornhäuser M. Feasibility of an exercise programme in elderly patients undergoing allogeneic stem cell transplantation - a pilot study. Eur J Cancer Care 2016;25:839-48. [DOI: 10.1111/ecc.12400] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
57 Estcourt LJ, Stanworth S, Doree C, Trivella M, Hopewell S, Blanco P, Murphy MF. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 2015;:CD010984. [PMID: 26505729 DOI: 10.1002/14651858.CD010984.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
58 Jobin C, Cloutier M, Simard C, Néron S. Heterogeneity of in vitro–cultured CD34+ cells isolated from peripheral blood. Cytotherapy 2015;17:1472-84. [DOI: 10.1016/j.jcyt.2015.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
59 Crighton GL, Estcourt LJ, Wood EM, Trivella M, Doree C, Stanworth S. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 2015;:CD010981. [PMID: 26422767 DOI: 10.1002/14651858.CD010981.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
60 Nivison-Smith I, Bardy P, Dodds AJ, Ma DDF, Aarons D, Tran S, Wilcox L, Szer J. A Review of Hematopoietic Cell Transplantation in Australia and New Zealand, 2005 to 2013. Biol Blood Marrow Transplant 2016;22:284-91. [PMID: 26385524 DOI: 10.1016/j.bbmt.2015.09.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
61 Haen SP, Schumm M, Faul C, Kanz L, Bethge WA, Vogel W. Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation. J Cancer Res Clin Oncol 2015;141:2241-51. [DOI: 10.1007/s00432-015-2027-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
62 Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. Biol Blood Marrow Transplant 2015;21:2091-9. [PMID: 26253007 DOI: 10.1016/j.bbmt.2015.07.028] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
63 Jiang Y, Wan L, Qin Y, Wang X, Yan S, Xie K, Wang C. Donor Chimerism of B Cells and Nature Killer Cells Provides Useful Information to Predict Hematologic Relapse following Allogeneic Hematopoietic Stem Cell Transplantation. PLoS One 2015;10:e0133671. [PMID: 26226104 DOI: 10.1371/journal.pone.0133671] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
64 Thurman-Newell JA, Petzing JN, Williams DJ. Quantification of biological variation in blood-based therapy--a summary of a meta-analysis to inform manufacturing in the clinic. Vox Sang 2015;109:394-402. [PMID: 26174339 DOI: 10.1111/vox.12288] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
65 Chen S, Smith BA, Iype J, Prestipino A, Pfeifer D, Grundmann S, Schmitt-Graeff A, Idzko M, Beck Y, Prinz G, Finke J, Duyster J, Zeiser R. MicroRNA-155-deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation. Blood 2015;126:103-12. [PMID: 25972159 DOI: 10.1182/blood-2014-12-617258] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 9.9] [Reference Citation Analysis]
66 Chabannon C, Bijou F, Miclea JM, Milpied N, Grouin JM, Mohty M. A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs. Transfusion 2015;55:2149-57. [PMID: 25968564 DOI: 10.1111/trf.13141] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
67 Morishita S, Kaida K, Yamauchi S, Wakasugi T, Ikegame K, Kodama N, Ogawa H, Domen K. Early-phase differences in health-related quality of life, psychological status, and physical function between human leucocyte antigen-haploidentical and other allogeneic haematopoietic stem cell transplantation recipients. Eur J Oncol Nurs 2015;19:443-50. [PMID: 25911269 DOI: 10.1016/j.ejon.2015.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
68 Sato M, Katayama Y. Osteocytes and Homeostasis of Remote Organs: Bone-Buried Osteocytes Talk to Remote Organs. Curr Osteoporos Rep 2015;13:193-7. [DOI: 10.1007/s11914-015-0269-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
69 Saußele S, Silver RT. Management of chronic myeloid leukemia in blast crisis. Ann Hematol 2015;94 Suppl 2:S159-65. [PMID: 25814082 DOI: 10.1007/s00277-015-2324-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
70 Barba P, Martino R, Martinez-cuadron D, Olga G, Esquirol A, Gil-cortés C, Gonzalez J, Fernandez-avilés F, Valcárcel D, Guardia R, Duarte RF, Hernandez-rivas JM, Abella E, Montesinos P, Ribera JM. Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia. Leukemia & Lymphoma 2015;56:2812-8. [DOI: 10.3109/10428194.2015.1014365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
71 Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, Gratwohl M, Bouzas LF, Confer D, Frauendorfer K, Gluckman E, Greinix H, Horowitz M, Iida M, Lipton J, Madrigal A, Mohty M, Noel L, Novitzky N, Nunez J, Oudshoorn M, Passweg J, van Rood J, Szer J, Blume K, Appelbaum FR, Kodera Y, Niederwieser D;  Worldwide Network for Blood and Marrow Transplantation (WBMT). One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2:e91-100. [PMID: 26687803 DOI: 10.1016/s2352-3026(15)00028-9] [Cited by in Crossref: 222] [Cited by in F6Publishing: 214] [Article Influence: 31.7] [Reference Citation Analysis]
72 Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M; European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015;50:476-82. [PMID: 25642761 DOI: 10.1038/bmt.2014.312] [Cited by in Crossref: 135] [Cited by in F6Publishing: 139] [Article Influence: 19.3] [Reference Citation Analysis]
73 Feucht J, Opherk K, Lang P, Kayser S, Hartl L, Bethge W, Matthes-Martin S, Bader P, Albert MH, Maecker-Kolhoff B, Greil J, Einsele H, Schlegel PG, Schuster FR, Kremens B, Rossig C, Gruhn B, Handgretinger R, Feuchtinger T. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 2015;125:1986-94. [PMID: 25617426 DOI: 10.1182/blood-2014-06-573725] [Cited by in Crossref: 88] [Cited by in F6Publishing: 81] [Article Influence: 12.6] [Reference Citation Analysis]
74 Nowak J, Kościńska K, Mika-Witkowska R, Rogatko-Koroś M, Mizia S, Jaskuła E, Polak M, Mordak-Domagała M, Lange J, Gronkowska A, Jędrzejczak WW, Kyrcz-Krzemień S, Markiewicz M, Dzierżak-Mietła M, Tomaszewska A, Nasiłowska-Adamska B, Szczepiński A, Hałaburda K, Hellmann A, Czyż A, Gil L, Komarnicki M, Wachowiak J, Barańska M, Kowalczyk J, Drabko K, Goździk J, Wysoczańska B, Bogunia-Kubik K, Graczyk-Pol E, Witkowska A, Marosz-Rudnicka A, Nestorowicz K, Dziopa J, Szlendak U, Warzocha K, Lange A; Polish Donor-Recipient Matching Study Group. Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 2015;21:829-39. [PMID: 25617806 DOI: 10.1016/j.bbmt.2015.01.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
75 Chabannon C, Hildebrandt M, Scheding S, Humpe A, Lowdell M, Slaper-cortenbach I. Regulation of advanced therapy medicinal products will affect the practice of haematopoietic SCT in the near future: a perspective from the EBMT cell-processing committee. Bone Marrow Transplant 2015;50:321-3. [DOI: 10.1038/bmt.2014.271] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
76 Ziakas PD, Zervou FN, Zacharioudakis IM, Mylonakis E. Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis. PLoS One 2014;9:e114735. [PMID: 25485632 DOI: 10.1371/journal.pone.0114735] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
77 Crucitti L, Crocchiolo R, Toffalori C, Mazzi B, Greco R, Signori A, Sizzano F, Chiesa L, Zino E, Lupo Stanghellini MT, Assanelli A, Carrabba MG, Marktel S, Marcatti M, Bordignon C, Corti C, Bernardi M, Peccatori J, Bonini C, Fleischhauer K, Ciceri F, Vago L. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia 2015;29:1143-52. [DOI: 10.1038/leu.2014.314] [Cited by in Crossref: 66] [Cited by in F6Publishing: 74] [Article Influence: 8.3] [Reference Citation Analysis]
78 Hechinger AK, Smith BA, Flynn R, Hanke K, McDonald-Hyman C, Taylor PA, Pfeifer D, Hackanson B, Leonhardt F, Prinz G, Dierbach H, Schmitt-Graeff A, Kovarik J, Blazar BR, Zeiser R. Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD. Blood 2015;125:570-80. [PMID: 25352130 DOI: 10.1182/blood-2014-06-581793] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
79 Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A, Antin JH, Bolwell BJ, Cahn JY, Cairo MS, Cutler CS, Flowers ME, Gale RP, Herzig R, Isola LM, Jacobsohn DA, Jagasia MH, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Spellman SR, Schouten HC, Verdonck LF, Wingard JR, Weisdorf DJ, Horowitz MM, Pavletic SZ. Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res 2015;21:2020-8. [PMID: 25348512 DOI: 10.1158/1078-0432.CCR-14-0586] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 7.8] [Reference Citation Analysis]
80 Estcourt LJ. Why has demand for platelet components increased? A review: Why has demand for platelet components increased? Transfusion Med 2014;24:260-8. [DOI: 10.1111/tme.12155] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
81 Roziakova L, Mistrik M, Batorova A, Kruzliak P, Bojtarova E, Dubrava J, Gergel J, Mladosievicova B. Can We Predict Clinical Cardiotoxicity with Cardiac Biomarkers in Patients After Haematopoietic Stem Cell Transplantation? Cardiovasc Toxicol 2015;15:210-6. [DOI: 10.1007/s12012-014-9286-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
82 Nowak J, Kościńska K, Mika-Witkowska R, Rogatko-Koroś M, Mizia S, Jaskuła E, Polak M, Mordak-Domagała M, Lange J, Gronkowska A, Jędrzejczak WW, Kyrcz-Krzemień S, Markiewicz M, Dzierżak-Mietła M, Tomaszewska A, Nasiłowska-Adamska B, Szczepiński A, Hałaburda K, Hellmann A, Komarnicki M, Gil L, Czyż A, Wachowiak J, Barańska M, Kowalczyk J, Drabko K, Goździk J, Wysoczańska B, Bogunia-Kubik K, Graczyk-Pol E, Witkowska A, Marosz-Rudnicka A, Nestorowicz K, Dziopa J, Szlendak U, Warzocha K, Lange AA; Polish Donor-Recipient Matching Study Group. Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients. Am J Hematol 2014;89:E176-83. [PMID: 25044365 DOI: 10.1002/ajh.23802] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
83 Kirsch M, Mitchell SA, Dobbels F, Stussi G, Basch E, Halter JP, De Geest S. Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation. Eur J Oncol Nurs 2015;19:66-74. [PMID: 25190633 DOI: 10.1016/j.ejon.2014.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
84 Clark JR, Scott SD, Jack AL, Lee H, Mason J, Carter GI, Pearce L, Jackson T, Clouston H, Sproul A, Keen L, Molloy K, Folarin N, Whitby L, Snowden JA, Reilly JT, Barnett D; United Kingdom National External Quality Assessment Service for Leucocyte Immunophenotyping Chimerism Working Group. Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service for Leucocyte Immunophenotyping Chimerism Working Group. Br J Haematol 2015;168:26-37. [PMID: 25145701 DOI: 10.1111/bjh.13073] [Cited by in Crossref: 61] [Cited by in F6Publishing: 73] [Article Influence: 7.6] [Reference Citation Analysis]
85 Morkis IVC, Farias MG, Rigoni LDC, Scotti L, Gregianin LJ, Daudt LE, Silla LMDR, Paz AA. Assessment of immature platelet fraction and immature reticulocyte fraction as predictors of engraftment after hematopoietic stem cell transplantation. Int Jnl Lab Hem 2015;37:259-64. [DOI: 10.1111/ijlh.12278] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
86 Chevallier P, Labopin M, Socié G, Tabrizi R, Furst S, Lioure B, Guillaume T, Delaunay J, de La Tour RP, Vigouroux S, El-Cheikh J, Blaise D, Michallet M, Bilger K, Milpied N, Moreau P, Mohty M. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. Haematologica 2014;99:1486-91. [PMID: 24951467 DOI: 10.3324/haematol.2014.108563] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
87 Benyamini N, Rowe JM. Is there a role for allogeneic transplantation in chronic myeloid leukemia? Expert Rev Hematol 2013;6:759-65. [PMID: 24219552 DOI: 10.1586/17474086.2013.849571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
88 Stern M, de Wreede LC, Brand R, van Biezen A, Dreger P, Mohty M, de Witte TM, Kröger N, Ruutu T. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia 2014;28:2235-40. [PMID: 24781016 DOI: 10.1038/leu.2014.145] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 7.4] [Reference Citation Analysis]
89 Czerw T, Labopin M, Gorin NC, Giebel S, Blaise D, Dumas PY, Foa R, Attal M, Schaap N, Michallet M, Bonmati C, Veelken H, Mohty M. Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant 2014;49:950-4. [PMID: 24710564 DOI: 10.1038/bmt.2014.64] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
90 Young ME, Potter V, Kulasekararaj AG, Mufti GJ, Marsh JC. Haematopoietic stem cell transplantation for acquired aplastic anaemia. Curr Opin Hematol 2013;20:515-20. [PMID: 24104412 DOI: 10.1097/MOH.0b013e328365af83] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
91 Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak GW, Bazarbachi A, Douglas K, Gabriel I, Garderet L, Geraldes C, Jaksic O, Kattan MW, Koristek Z, Lanza F, Lemoli RM, Mendeleeva L, Mikala G, Mikhailova N, Nagler A, Schouten HC, Selleslag D, Suciu S, Sureda A, Worel N, Wuchter P, Chabannon C, Duarte RF. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2014;49:865-72. [PMID: 24686988 DOI: 10.1038/bmt.2014.39] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 11.3] [Reference Citation Analysis]
92 Estcourt LJ, Gregg R, Stanworth S, Doree C, Trivella M, Murphy MF, Tinmouth A. Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 2014:CD010982. [PMID: 25722650 DOI: 10.1002/14651858.CD010982] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
93 Passweg JR, Baldomero H, Peters C, Gaspar HB, Cesaro S, Dreger P, Duarte RF, Falkenburg JH, Farge-Bancel D, Gennery A, Halter J, Kröger N, Lanza F, Marsh J, Mohty M, Sureda A, Velardi A, Madrigal A; European Society for Blood and Marrow Transplantation EBMT. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014;49:744-50. [PMID: 24637898 DOI: 10.1038/bmt.2014.55] [Cited by in Crossref: 110] [Cited by in F6Publishing: 101] [Article Influence: 13.8] [Reference Citation Analysis]
94 Bouazzaoui A, Dickhöfer S, Kreuz M, Huber E, Holler E, Wolff D. Cytostatic conditioning in experimental allogeneic bone marrow transplantation: Busulfan causes less early gastrointestinal toxicity but Treosulfan results in improved immune reconstitution. Immunopharmacol Immunotoxicol 2014;36:158-64. [PMID: 24588615 DOI: 10.3109/08923973.2014.895743] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
95 Bettens F, Brunet L, Tiercy J. High-allelic variability in HLA-C mRNA expression: association with HLA-extended haplotypes. Genes Immun 2014;15:176-81. [DOI: 10.1038/gene.2014.1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
96 Golubeva V, Mikhalevich J, Novikova J, Tupizina O, Trofimova S, Zueva Y. Novel cell population data from a haematology analyzer can predict timing and efficiency of stem cell transplantation. Transfusion and Apheresis Science 2014;50:39-45. [DOI: 10.1016/j.transci.2013.12.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
97 Hefner J, Kapp M, Drebinger K, Dannenmann A, Einsele H, Grigoleit GU, Faller H, Csef H, Mielke S. High prevalence of distress in patients after allogeneic hematopoietic SCT: fear of progression is associated with a younger age. Bone Marrow Transplant. 2014;49:581-584. [PMID: 24442247 DOI: 10.1038/bmt.2013.228] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
98 Ziakas PD, Kourbeti IS, Mylonakis E. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Clin Ther 2014;36:292-306.e1. [PMID: 24439393 DOI: 10.1016/j.clinthera.2013.11.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
99 Xhaard A, Rzepecki P, Valcarcel D, Santarone S, Fürst S, Serrano D, De Angelis G, Krüger W, Scheid C. Optimization of health-care organization and perceived improvement of patient comfort by switching from intra-venous BU four-times-daily infusions to a once-daily administration scheme in adult hematopoietic stem cell recipients. Bone Marrow Transplant 2014;49:509-12. [PMID: 24419513 DOI: 10.1038/bmt.2013.220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
100 Lown RN, Marsh SG, Switzer GE, Latham KA, Madrigal JA, Shaw BE. Ethnicity, length of time on the register and sex predict donor availability at the confirmatory typing stage. Bone Marrow Transplant 2014;49:525-31. [PMID: 24419516 DOI: 10.1038/bmt.2013.206] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
101 Roug AS, Hokland LB, Segel E, Nielsen K, Toft-Petersen M, Van Kooten Niekerk PB, Hokland P, Nederby L. Unraveling stem cell and progenitor subsets in autologous grafts according to methods of mobilization: implications for prediction of hematopoietic recovery. Cytotherapy 2014;16:392-401. [PMID: 24424268 DOI: 10.1016/j.jcyt.2013.11.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
102 Atsuta Y, Suzuki R, Yamashita T, Fukuda T, Miyamura K, Taniguchi S, Iida H, Uchida T, Ikegame K, Takahashi S. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. Ann Oncol. 2014;25:435-441. [PMID: 24399081 DOI: 10.1093/annonc/mdt558] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 7.5] [Reference Citation Analysis]
103 Yang K, Si Y, Chen H, He X, Lou J, Bai X, Du J, Guo Z, Chen P. Comparative study of the efficacy of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-haploidentical related and unrelated donors in the treatment of leukemia. Acta Haematol 2014;131:37-44. [PMID: 24029046 DOI: 10.1159/000353776] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
104 Bucher CM, Passweg JR. Towards rational graft-versus-host disease prophylaxis. Haematologica 2012;97:1779-80. [PMID: 23204477 DOI: 10.3324/haematol.2012.080226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
105 Holbro A, Graf L, Topalidou M, Bucher C, Passweg JR, Tsakiris DA. Cryopreserved stem cell products containing dimethyl sulfoxide lead to activation of the coagulation system without any impact on engraftment. Transfusion 2014;54:1508-14. [PMID: 24304039 DOI: 10.1111/trf.12511] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
106 Chevallier P, Labopin M, Milpied N, Bilger K, Socié G, Yakoub-Agha I, Michallet M, Bulabois CE, Maury S, Beguin Y, Bay JO, Blaise D, Maillard N, Guillerm G, Daguindeau E, Raus N, Mohty M. Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2014;49:361-5. [PMID: 24292522 DOI: 10.1038/bmt.2013.186] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
107 Martino M, Postorino M, Gallo GA, Messina G, Neri S, Piro E, Gentile M, Moscato T, Monteleone R, Fedele R, Mazzone C, Console G, Penna G, Alati C, Vincelli ID, Irrera G, Musolino C, Ronco F, Molica S, Morabito F. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs. Clin Lymphoma Myeloma Leuk 2014;14:148-54. [PMID: 24417912 DOI: 10.1016/j.clml.2013.11.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
108 Labopin M, Gorin N, Polge E, Socié G, Gurman G, Gluckman E, Jindra P, Poiré X, Schäfer-eckart K, Ruutu T, Milone G, Arcese W, Mohty M, Rocha V; on behalf of the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow transplantation (EBMT). A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. Bone Marrow Transplant 2014;49:376-81. [DOI: 10.1038/bmt.2013.178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
109 Gratwohl A, Baldomero H, Passweg J. Hematopoietic stem cell transplantation activity in Europe: . Current Opinion in Hematology 2013;20:485-93. [DOI: 10.1097/moh.0b013e328364f573] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
110 Tripura C, Pande G. Applications of human hematopoietic stem cells isolated and expanded from different tissues in regenerative medicine. Regenerative Medicine 2013;8:783-95. [DOI: 10.2217/rme.13.75] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
111 Bontant T, Sedlaçek P, Balduzzi A, Gaspar B, Cesaro S, Einsele H, Peters C, Dalle J. Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the Inborn Errors, Infectious Diseases and Pediatric Diseases Working Parties of EBMT. Bone Marrow Transplant 2014;49:276-9. [DOI: 10.1038/bmt.2013.164] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
112 Olivieri J, Pierelli L, Introna M, Accorsi P, Bosi A, Perseghin P, Risso M, Pandolfi A, Mancini S, Marchetti M, Dal Pozzo S, Gotti E, Rambaldi A, Leoni P, Olivieri A; Gitmo (Gruppo Italiano Trapianto di Midollo Osseo)–SIDEM (Società Italiana di Emaferesi e Manipolazione Cellulare) Working Group on SCU Disposal. Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. Cytotherapy 2014;16:101-10. [PMID: 24169075 DOI: 10.1016/j.jcyt.2013.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
113 Braamse AM, van Meijel B, Visser O, Huijgens PC, Beekman AT, Dekker J. Distress, problems and supportive care needs of patients treated with auto- or allo-SCT. Bone Marrow Transplant 2014;49:292-8. [PMID: 24096825 DOI: 10.1038/bmt.2013.155] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
114 Wong Doo N, Coory M, White V, Harrison SJ, Prince HM, Millar JL, Dimech M, Giles GG; IMPROVE Project. Low uptake of upfront autologous transplantation for myeloma in a jurisdiction with universal health care coverage: a population-based patterns of care study in Australia. Clin Lymphoma Myeloma Leuk 2014;14:61-7. [PMID: 24210724 DOI: 10.1016/j.clml.2013.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
115 Schmidt M, Sonneville R, Schnell D, Bigé N, Hamidfar R, Mongardon N, Castelain V, Razazi K, Marty A, Vincent F, Dres M, Gaudry S, Luyt CE, Das V, Micol JB, Demoule A, Mayaux J. Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter study. Clin Infect Dis 2013;57:1535-41. [PMID: 23994819 DOI: 10.1093/cid/cit557] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
116 Mueller SM, Haeusermann P, Rovó A, Halter JP, Passweg J, Itin P, Tichelli A. Genital chronic GVHD in men after hematopoietic stem cell transplantation: a single-center cross-sectional analysis of 155 patients. Biol Blood Marrow Transplant 2013;19:1574-80. [PMID: 23962394 DOI: 10.1016/j.bbmt.2013.07.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
117 Peinemann F, Smith LA, Bartel C. Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas. Cochrane Database Syst Rev 2013;:CD008216. [PMID: 23925699 DOI: 10.1002/14651858.CD008216.pub4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
118 Servais S, Beguin Y, Baron F. Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Emerging Drugs 2013;18:173-92. [DOI: 10.1517/14728214.2013.798642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
119 Moscato T, Fedele R, Messina G, Irrera G, Console G, Martino M. Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma. Expert Opin Biol Ther 2013;13:1013-27. [PMID: 23586758 DOI: 10.1517/14712598.2013.779250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
120 Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF, Falkenburg JH, Kröger N, Farge-Bancel D, Gaspar HB, Marsh J, Mohty M, Peters C, Sureda A, Velardi A, Ruiz de Elvira C, Madrigal A; European Group for Blood and Marrow Transplantation. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant 2013;48:1161-7. [PMID: 23584439 DOI: 10.1038/bmt.2013.51] [Cited by in Crossref: 84] [Cited by in F6Publishing: 85] [Article Influence: 9.3] [Reference Citation Analysis]
121 Martino M, Olivieri A, Offidani M, Vigna E, Moscato T, Fedele R, Montanari M, Console G, Gentile M, Messina G, Irrera G, Morabito F. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opinion on Investigational Drugs 2013;22:619-34. [DOI: 10.1517/13543784.2013.788643] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
122 Passera R, Pollichieni S, Brunello L, Patriarca F, Bonifazi F, Montefusco V, Falda M, Montanari M, Guidi S, Giaccone L, Mordini N, Carella AM, Bavaro P, Milone G, Benedetti F, Ciceri F, Scimè R, Benedetti E, Castagna L, Festuccia M, Rambaldi A, Bacigalupo A, Corradini P, Bosi A, Boccadoro M, Bandini G, Fanin R, Bruno B. Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. Biol Blood Marrow Transplant 2013;19:940-8. [PMID: 23538113 DOI: 10.1016/j.bbmt.2013.03.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
123 Sengeløv H, Gerds TA, Brændstrup P, Kornblit B, Mortensen BK, Petersen SL, Vindeløv LL. Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission: single-centre results after TBI-based myeloablative and non-myeloablative conditioning. Bone Marrow Transplant 2013;48:1185-91. [DOI: 10.1038/bmt.2013.38] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
124 Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. Biol Blood Marrow Transplant. 2013;19:934-939. [PMID: 23523970 DOI: 10.1016/j.bbmt.2013.03.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
125 Vago L, Toffalori C, Ciceri F, Fleischhauer K. Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia. Semin Oncol 2012;39:707-15. [PMID: 23206847 DOI: 10.1053/j.seminoncol.2012.09.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
126 Morishita S, Kaida K, Yamauchi S, Sota K, Ishii S, Ikegame K, Kodama N, Ogawa H, Domen K. Relationship between corticosteroid dose and declines in physical function among allogeneic hematopoietic stem cell transplantation patients. Support Care Cancer 2013;21:2161-9. [DOI: 10.1007/s00520-013-1778-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
127 Le Bourgeois A, Lestang E, Guillaume T, Delaunay J, Ayari S, Blin N, Clavert A, Tessoulin B, Dubruille V, Mahe B, Roland V, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Chevallier P. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT). Eur J Haematol 2013;90:177-86. [DOI: 10.1111/ejh.12049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
128 Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A; on behalf of the Late Effects Working Party of the EBMT. Paternity wishes in long-term survivors after allogeneic hematopoietic SCT. A study of the late effects working party of the EBMT. Bone Marrow Transplant 2013;48:878-9. [DOI: 10.1038/bmt.2012.255] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
129 Cesaro S, Nesi F, Tridello G, Abate M, Panizzolo IS, Balter R, Calore E. A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. PLoS One 2013;8:e53252. [PMID: 23308174 DOI: 10.1371/journal.pone.0053252] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
130 Chang YJ, Huang XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom? Blood Rev 2013;27:55-62. [PMID: 23261066 DOI: 10.1016/j.blre.2012.11.002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
131 Phillips GL. Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): How can we improve outcomes in the near future? Leukemia Research 2012;36:1490-5. [DOI: 10.1016/j.leukres.2012.08.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
132 Passweg JR, Aljurf M. Treatment and hematopoietic SCT in aplastic anemia. Bone Marrow Transplant 2013;48:161. [PMID: 23165496 DOI: 10.1038/bmt.2012.229] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
133 Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM, Vazquez L, Perez Rivera JA, Martin-Herrero F, Sanchez-Barba M, Guerrero C, del Cañizo MC, Caballero MD, San Miguel JF, Alberca I, Gonzalez-Porras JR. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica 2013;98:437-43. [PMID: 22899581 DOI: 10.3324/haematol.2012.069559] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]